PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
1.76%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.08%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
1.51%
ROA exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.44%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.
-0.50%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.02%. Seth Klarman would investigate whether a turnaround is viable.
83.47%
Gross margin 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 58.57%. Mohnish Pabrai would verify if a unique value chain offers pricing benefits.
-39.34%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 2.76%. Seth Klarman would look for a path to operational turnaround.
126.07%
Net margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.74%. Joel Greenblatt would see if this advantage is sustainable across cycles.